Last reviewed · How we verify
atherosclerosis vaccine
An immunotherapeutic vaccine that stimulates the immune system to recognize and attack oxidized lipoproteins and atherosclerotic plaques.
An immunotherapeutic vaccine that stimulates the immune system to recognize and attack oxidized lipoproteins and atherosclerotic plaques. Used for Atherosclerosis (cardiovascular disease prevention and progression reduction).
At a glance
| Generic name | atherosclerosis vaccine |
|---|---|
| Sponsor | Immunitor LLC |
| Drug class | Therapeutic vaccine |
| Target | Oxidized low-density lipoprotein (oxLDL) and atherosclerotic plaque antigens |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The atherosclerosis vaccine works by training the adaptive immune system to target pathogenic antigens associated with atherosclerotic lesions, particularly oxidized low-density lipoprotein (oxLDL) and related epitopes. By promoting a therapeutic immune response against these disease-associated antigens, the vaccine aims to reduce plaque progression, stabilize existing lesions, and lower cardiovascular event risk in patients with established atherosclerotic disease.
Approved indications
- Atherosclerosis (cardiovascular disease prevention and progression reduction)
Common side effects
- Injection site reactions
- Mild systemic inflammation
- Fever
Key clinical trials
- Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease (PHASE4)
- Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity (PHASE3)
- Flu Vaccination in Congestive Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |